Celldex Therapeutics, Inc. (CLDX) earnings
CLDX earnings moved a median of +1.92% by the close. Quarterly and annual CLDX reports and results, each read against the price at its own news timestamp. Back to the CLDX overview →
19 measured CLDX earnings events.
Where these CLDX earnings landedvs 19 measured CLDX earnings reactions
| Middle 50% of CLDX earnings reactions | -0.05% to +2.78% |
|---|---|
| Median reaction (to close) | +1.92% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 CLDX earnings events with a measured close landed between -0.05% and +2.78%; 74% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Celldex Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.85% | -0.38% | |
| Form 10-Q Celldex Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.38% | -2.78% | |
| Form 10-K Celldex Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.39% | -0.74% | |
| Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +1.84% | +9.58% | |
| Form 10-Q Celldex Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.84% | +9.58% | |
| Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +4.19% | +1.92% | |
| Form 10-Q Celldex Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +4.19% | +1.92% | |
| Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +7.25% | +0.71% | |
| Form 10-Q Celldex Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +7.25% | +0.71% | |
| Form 10-K Celldex Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.38% | +3.37% | |
| Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.21% | -5.46% | |
| Form 10-Q Celldex Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.21% | -5.46% | |
| Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.40% | +0.27% | |
| Form 10-Q Celldex Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.40% | +0.27% | |
| Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.10% | +2.78% | |
| Form 10-Q Celldex Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.10% | +2.78% | |
| Form 10-K Celldex Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +4.12% | +22.97% | |
| Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +0.00% | +2.28% | |
| Form 10-Q Celldex Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +2.28% |
Keep exploring
More CLDX: analyst actions → · SEC filings → · CLDX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 257 | -0.63% | 42% |
| Addus HomeCare Corporation (ADUS) | 256 | -0.02% | 47% |
| Prothena Corporation plc - Ordinary Shares (PRTA) | 256 | -0.04% | 49% |
| Xeris Biopharma Holdings, Inc. (XERS) | 256 | +0.32% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.